Abstract：
Neuromyotonia is a rare peripheral nerve hyperexcitability syndrome often associated with antibodies directed against contactin-associated protein-like 2 and leucine-rich, glioma inactivated 1. The quadrivalent human papilloma virus vaccine Gardasil®, first approved in 2006, is known to be a highly effective prophylaxis against papillomavirus types 6, 11, 16, and 18. Molecularly, this non-infectious recombinant vaccine is based on purified L1 proteins from the human papilloma virus capsid. Since the approval of this vaccine, several studies have investigated its safety regarding the occurrence of autoimmune conditions following application. Here, we present the first case of neuromyotonia with active Gadolinium enhancing demyelinating central nervous system lesions following vaccination with Gardasil®.
摘要：
神经肌强直是一种罕见的周围神经兴奋过度综合征，通常与针对contactin相关蛋白样2和富含亮氨酸的抗体有关。胶质瘤灭活1.四价人乳头瘤病毒疫苗Gardasil®，2006年首次获得批准，已知是对乳头瘤病毒6型、11型、16型和18型的高效预防。分子上，这种非感染性重组疫苗是基于从人乳头瘤病毒衣壳中纯化的L1蛋白。自从这种疫苗获得批准以来，几项研究已经调查了其在应用后发生自身免疫性疾病的安全性。这里,我们介绍了第一例Gardasil®疫苗接种后，神经肌强直伴活性钆增强中枢神经系统脱髓鞘病变的病例。
